Sign in

You're signed outSign in or to get full access.

Weili Dai

Director at Astrana Health
Board

About Weili Dai

Independent director of Astrana Health (ASTH), age 63, serving since 2021. Co‑founder and former President/Director of Marvell Technology (to 2016); co‑founder and Executive Chairwoman of MeetKai (since 2018); Chair of Lark Technologies. B.S. in Computer Science from UC Berkeley; recognized on Forbes “World’s Most Powerful Women” and as EY Entrepreneur of the Year .

Past Roles

OrganizationRoleTenureCommittees/Impact
Marvell TechnologyCo‑founder; President and DirectorUntil 2016Built global semiconductor company; technology leadership credentials

External Roles

OrganizationRoleTenureNotes
MeetKai, Inc.Executive Chairwoman2018–PresentAI‑enabled conversational search; co‑founder
Lark Technologies, Inc.Chairman of the BoardNot disclosedHealthcare tech company; conversational AI care

Board Governance

  • Independence: Board affirmatively determined Weili Dai is independent under Nasdaq and SEC rules; all standing committees comprise independent directors .
  • Committee assignments: None; not currently on Audit, Compensation, or Nominating & Corporate Governance committees .
  • Attendance: The Board met 11 times in 2024; “each of our incumbent directors, except Ms. Dai, attended 75% or more” of Board and committee meetings—indicating Dai fell below the 75% threshold (red flag for engagement) .
  • Executive sessions and leadership: Lead Independent Director (Kitayama) leads independent sessions; Dai does not hold Lead Director or chair roles .
Governance AttributeStatus/Detail
Independent DirectorYes
Director Since2021
CommitteesNone
2024 AttendanceBelow 75% threshold (Board held 11 meetings)
Lead Independent DirectorNot applicable (held by Kitayama)

Fixed Compensation

Astrana’s July 2024 non‑employee director program: $80,000 annual cash retainer; Chair/member committee retainers; annual restricted stock grant $170,000 grant‑date value, vesting by first anniversary or next annual meeting .

YearFees Earned (Cash)Equity Awards (Grant-Date FV)Total
2024$80,004 $169,967 $249,971
  • Program details: Audit Chair $25,000; Comp Chair $20,000; Nominating Chair $15,000; Audit member $12,000; Comp member $10,000; Nominating member $10,000; additional $32,500 for Lead Director/Board Chair (not applicable to Dai) .

Performance Compensation

  • No performance‑based director equity disclosed; annual director grants are time‑based restricted stock vesting by the next annual meeting/first anniversary .

No director performance metrics (TSR, EBITDA, ESG) apply to non‑employee director awards .

Other Directorships & Interlocks

  • No Astrana‑disclosed related‑party transactions or shared directorships involving Weili Dai; related‑party section lists transactions tied to Lam, Sim, Marsh, Estradas, Young and affiliates, but not Dai .

Expertise & Qualifications

  • Deep technology and AI background (semiconductors, conversational AI) with executive/board leadership at Marvell, MeetKai, Lark .
  • Recognitions (Forbes Most Powerful Women; EY Entrepreneur of the Year) underscore influence and network .
  • Education: B.S. Computer Science, UC Berkeley .

Equity Ownership

ItemAmount
Beneficial Ownership (Common Shares)7,214 shares (<1%)
Unvested Restricted Stock Outstanding (12/31/2024)3,564 shares
Stock Options Outstanding0
  • Ownership guidelines: Non‑employee directors must hold 3× annual cash retainer; five years to comply (April 2024 adoption → compliance by April 2029). Until met, must retain at least 50% of shares received (net of taxes/exercise) .

Insider Trades & Filings

2024 Section 16(a) Filing TimelinessNotes
TimelyCompany reports only two late Form 4 filings—Brandon K. Sim and Chandan Basho; no delinquencies noted for Weili Dai

Governance Assessment

  • Strengths: Independent director with strong technology/AI credentials; standard, market‑aligned director pay structure; subject to stock ownership guidelines and clawback policy; insider trading policy restricts hedging/pledging (alignment) .
  • Concerns:
    • Attendance: Failing to meet the 75% threshold in 2024 is a material engagement red flag; may affect board effectiveness and investor confidence if persistent .
    • Committee leverage: No committee memberships limits direct influence on audit/compensation/governance oversight .
    • Ownership alignment: Beneficial holdings are small (<1%); reliance on annual RS grants for alignment, with guideline compliance timeline through 2029 .
  • Conflicts/Related‑Party Exposure: None disclosed for Dai; related‑party transactions detailed for other directors/executives (Lam, Sim, Marsh, Estradas, Young), not Dai—reduces conflict risk profile .

Overall: Dai brings valuable tech/AI expertise but should improve attendance and consider committee engagement to enhance governance impact. No disclosed conflicts and standard director compensation/ownership policies support alignment, yet low ownership and limited committee roles temper investor confidence pending improved participation .